129 related articles for article (PubMed ID: 8640926)
1. Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients.
Phillips DH; Hewer A; Grover PL; Poon GK; Carmichael PL
Carcinogenesis; 1996 May; 17(5):1149-52. PubMed ID: 8640926
[TBL] [Abstract][Full Text] [Related]
2. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients.
Hemminki K; Rajaniemi H; Koskinen M; Hansson J
Carcinogenesis; 1997 Jan; 18(1):9-13. PubMed ID: 9054583
[TBL] [Abstract][Full Text] [Related]
4. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
[TBL] [Abstract][Full Text] [Related]
5. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen.
Martin EA; Rich KJ; White IN; Woods KL; Powles TJ; Smith LL
Carcinogenesis; 1995 Jul; 16(7):1651-4. PubMed ID: 7614701
[TBL] [Abstract][Full Text] [Related]
6. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients.
Bartsch H; Phillips DH; Nair J; Hewer A; Meyberg-Solomeyer G; Grischke EM
Carcinogenesis; 2000 Apr; 21(4):845-7. PubMed ID: 10753226
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
Hemminki K; Rajaniemi H; Lindahl B; Moberger B
Cancer Res; 1996 Oct; 56(19):4374-7. PubMed ID: 8813128
[TBL] [Abstract][Full Text] [Related]
8. DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver.
Rajaniemi H; Koskinen M; Mäntylä E; Hemminki K
Toxicol Lett; 1998 Dec; 102-103():453-7. PubMed ID: 10022295
[TBL] [Abstract][Full Text] [Related]
9. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
[TBL] [Abstract][Full Text] [Related]
10. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
[TBL] [Abstract][Full Text] [Related]
11. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes.
Phillips DH; Carmichael PL; Hewer A; Cole KJ; Hardcastle IR; Poon GK; Keogh A; Strain AJ
Carcinogenesis; 1996 Jan; 17(1):89-94. PubMed ID: 8565142
[TBL] [Abstract][Full Text] [Related]
12. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
13. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium.
Carmichael PL; Sardar S; Crooks N; Neven P; Van Hoof I; Ugwumadu A; Bourne T; Tomas E; Hellberg P; Hewer AJ; Phillips DH
Carcinogenesis; 1999 Feb; 20(2):339-42. PubMed ID: 10069474
[TBL] [Abstract][Full Text] [Related]
15. Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system.
Shibutani S; Reardon JT; Suzuki N; Sancar A
Cancer Res; 2000 May; 60(10):2607-10. PubMed ID: 10825130
[TBL] [Abstract][Full Text] [Related]
16. The tamoxifen dilemma.
White IN
Carcinogenesis; 1999 Jul; 20(7):1153-60. PubMed ID: 10383884
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture.
Sharma M; Shubert DE; Sharma M; Rodabaugh KJ; McGarrigle BP; Vezina CM; Bofinger DP; Olson JR
Biochem Biophys Res Commun; 2003 Jul; 307(1):157-64. PubMed ID: 12849995
[TBL] [Abstract][Full Text] [Related]
18. Detection of tamoxifen-DNA adducts on lacI genes using DNA polymerase stop assay.
Cheng RH; Gant TW
Changgeng Yi Xue Za Zhi; 1999 Jun; 22(2):189-96. PubMed ID: 10493022
[TBL] [Abstract][Full Text] [Related]
19. Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer.
Gallicchio L; Tkaczuk K; Lord G; Danton M; Lewis LM; Lim CK; Flaws JA
Cancer Lett; 2004 Jul; 211(1):57-67. PubMed ID: 15194217
[TBL] [Abstract][Full Text] [Related]
20. 32P-postlabelling determination of DNA adducts of malonaldehyde in humans: total white blood cells and breast tissue.
Vaca CE; Fang JL; Mutanen M; Valsta L
Carcinogenesis; 1995 Aug; 16(8):1847-51. PubMed ID: 7634413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
